Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Craig E. Hunsaker Sells 13,878 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Craig E. Hunsaker sold 13,878 shares of Alphatec stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $12.36, for a total transaction of $171,532.08. Following the completion of the sale, the executive vice president now directly owns 1,450,018 shares in the company, valued at $17,922,222.48. This trade represents a 0.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Alphatec Stock Up 2.3%

Shares of Alphatec stock opened at $12.73 on Monday. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -9.95 and a beta of 1.10. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.14. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The company’s 50 day moving average price is $11.52 and its 200-day moving average price is $10.77.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business had revenue of $169.18 million during the quarter, compared to the consensus estimate of $167.57 million. During the same quarter in the prior year, the business posted ($0.34) earnings per share. Alphatec’s quarterly revenue was up 22.2% compared to the same quarter last year. Equities research analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ATEC. Piper Sandler restated an “overweight” rating and issued a $15.00 price objective (up from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research report on Monday, April 14th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 target price on shares of Alphatec in a research report on Friday, May 2nd. Finally, Wall Street Zen upgraded Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.89.

Hedge Funds Weigh In On Alphatec

Institutional investors have recently bought and sold shares of the stock. Comerica Bank grew its stake in Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 1,248 shares during the period. Quarry LP increased its position in shares of Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock valued at $49,000 after acquiring an additional 2,375 shares in the last quarter. Larson Financial Group LLC purchased a new position in shares of Alphatec in the first quarter worth $54,000. Lazard Asset Management LLC purchased a new position in Alphatec in the 4th quarter worth about $76,000. Finally, AlphaQuest LLC purchased a new position in shares of Alphatec during the fourth quarter valued at approximately $80,000. 66.35% of the stock is owned by institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.